CR10743A - Derivados de azaadamantano y metodos de uso de los mismos - Google Patents

Derivados de azaadamantano y metodos de uso de los mismos

Info

Publication number
CR10743A
CR10743A CR10743A CR10743A CR10743A CR 10743 A CR10743 A CR 10743A CR 10743 A CR10743 A CR 10743A CR 10743 A CR10743 A CR 10743A CR 10743 A CR10743 A CR 10743A
Authority
CR
Costa Rica
Prior art keywords
azaadamantano
derivatives
methods
same
Prior art date
Application number
CR10743A
Other languages
English (en)
Inventor
Michael R Schrimpf
Diana L Nersesian
Kevin B Sippy
Jianjuo Ji
Tao Li
Marc Scanio
Chih-Hund Lee
William H Bunnelle
Geoff G Z Zhang
Paul J Brackemeyer
Shuang Chen
Rodger F Henry
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39594848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/935,257 external-priority patent/US20080122023A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR10743A publication Critical patent/CR10743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
CR10743A 2006-11-06 2009-04-23 Derivados de azaadamantano y metodos de uso de los mismos CR10743A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85699206P 2006-11-06 2006-11-06
US90814307P 2007-03-26 2007-03-26
US11/935,257 US20080122023A1 (en) 2006-11-29 2007-11-05 Method of manufacturing cmos image sensor

Publications (1)

Publication Number Publication Date
CR10743A true CR10743A (es) 2009-06-05

Family

ID=39594848

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10743A CR10743A (es) 2006-11-06 2009-04-23 Derivados de azaadamantano y metodos de uso de los mismos
CR20140277A CR20140277A (es) 2006-11-06 2014-06-13 Derivados de azaadamantano y métodos de uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140277A CR20140277A (es) 2006-11-06 2014-06-13 Derivados de azaadamantano y métodos de uso de los mismos

Country Status (28)

Country Link
US (3) US8314119B2 (es)
EP (1) EP2099795B1 (es)
JP (4) JP5275246B2 (es)
KR (4) KR20140054300A (es)
CN (1) CN103554107B (es)
AU (1) AU2007316480B2 (es)
BR (1) BRPI0718028A2 (es)
CA (1) CA2668962C (es)
CO (1) CO6210720A2 (es)
CR (2) CR10743A (es)
DK (1) DK2099795T3 (es)
DO (3) DOP2011000301A (es)
EC (1) ECSP099388A (es)
ES (1) ES2551117T3 (es)
IL (2) IL198587A (es)
MX (2) MX340064B (es)
MY (1) MY148253A (es)
NO (1) NO20092181L (es)
NZ (4) NZ577474A (es)
PH (1) PH12013500745A1 (es)
PL (1) PL2099795T3 (es)
PT (1) PT2099795E (es)
RU (2) RU2450002C2 (es)
SG (1) SG176473A1 (es)
TW (1) TWI511729B (es)
UA (1) UA96961C2 (es)
WO (1) WO2008058096A2 (es)
ZA (3) ZA200903944B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
AU2008326784B2 (en) * 2007-11-20 2014-04-24 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2010145208A1 (en) * 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
HUE028435T2 (en) * 2010-09-02 2016-12-28 Suven Life Sciences Ltd Heterocyclic compounds as histamine H3 receptor ligands
CN103180321A (zh) * 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
MX2013008704A (es) 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
US8802693B1 (en) * 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
CA2852268C (en) 2011-10-20 2020-08-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317056A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonists and methods of correlating comt snps
CA2894384C (en) 2012-12-11 2018-03-06 Novartis Ag Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
JP6338223B2 (ja) 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
KR101879921B1 (ko) 2013-01-15 2018-07-18 노파르티스 아게 기면증의 치료를 위한 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
ES2865736T3 (es) 2013-01-15 2021-10-15 Novartis Ag Uso de agonistas del receptor de acetilcolina nicotínico alfa 7
WO2014164682A1 (en) * 2013-03-12 2014-10-09 Abbvie Inc. Azaadamantane formate ester and process preparing azaadamantane derivatives
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
JP6638716B2 (ja) * 2017-11-20 2020-01-29 コベルコ建機株式会社 建設機械のカーボディ
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
CN109232474B (zh) * 2018-09-27 2021-08-06 武汉尚赛光电科技有限公司 1,2,4-噻二唑类化合物及其制备方法和用途
EP3920910A4 (en) * 2019-02-04 2022-11-09 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11130743B2 (en) 2019-02-21 2021-09-28 Marquette University Heterocyclic ligands of PAR1 and methods of use
WO2020172609A1 (en) * 2019-02-21 2020-08-27 Marquette University Heterocyclic ligands of par1 and methods of use
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514006A1 (fr) 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
EP0088484A1 (en) 1982-02-04 1983-09-14 Fbc Limited Herbicidal thiadiazolyl N-aminoureas
GB8523211D0 (en) * 1985-09-19 1985-10-23 Beecham Group Plc Compounds
US4950759A (en) * 1988-07-07 1990-08-21 Duphar International Research B.V. Substituted 1,7-annelated 1H-indazoles
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) * 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5821370A (en) 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
CA2239301A1 (en) 1995-12-06 1997-06-12 Charles Howard Mitch Composition for treating pain
WO1998027983A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
US7732163B2 (en) * 1997-08-21 2010-06-08 Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US8236500B2 (en) * 1997-10-23 2012-08-07 The United States Of America, As Represented By The Department Of Veterans Affairs Promoter variants of the alpha-7 nicotinic acetylcholine receptor
US6875606B1 (en) * 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
NZ504436A (en) * 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6057446A (en) * 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
EP1068208B1 (en) * 1998-04-02 2003-05-14 Targacept, Inc. Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US5986100A (en) * 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
CA2333951C (en) * 1998-06-01 2012-02-28 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
YU13301A (sh) * 1998-08-18 2005-06-10 Ucb S.A. Muskarinski agonisti i antagonisti
DE60008866T2 (de) * 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US20010031771A1 (en) * 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
WO2000071520A2 (en) 1999-05-24 2000-11-30 Targacept, Inc. Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
JP2003530542A (ja) 1999-12-01 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経変性疾患の診断方法
US7060699B2 (en) 2000-07-04 2006-06-13 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
JP4225787B2 (ja) 2001-03-27 2009-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
PL374384A1 (en) * 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
MXPA04010966A (es) 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
US7049374B2 (en) 2002-07-18 2006-05-23 Chevron U.S.A. Inc. Heterodiamondoids
CA2493245A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2004229237B2 (en) * 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
CA2551486A1 (en) * 2003-12-22 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP2005232071A (ja) 2004-02-19 2005-09-02 Kanto Chem Co Inc ピラゾール誘導体
JP2007535553A (ja) * 2004-04-29 2007-12-06 アボット・ラボラトリーズ アミノ−テトラゾール類縁体および使用方法
MY148480A (en) * 2004-05-24 2013-04-30 Amgen Inc Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
FR2872165B1 (fr) * 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005267093B2 (en) 2004-07-23 2009-10-01 Nuada Llc Peptidase inhibitors
DE602005020462D1 (de) * 2004-08-25 2010-05-20 Essentialis Inc Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
WO2006040352A1 (en) * 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
DE602005025667D1 (de) 2004-10-20 2011-02-10 Neurosearch As Neue diazabizyklische arylderivate und medizinische verwendung dafür
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
US9274099B2 (en) * 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
RU2008110911A (ru) 2005-12-06 2010-01-20 Ньюросерч А/С (DK) Новые диазабициклические арильные производные и их медицинское применение
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
SG178000A1 (en) * 2006-10-27 2012-02-28 Medivation Neurology Inc Methods and combination therapies for treating alzheimer's disease
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8367696B2 (en) * 2007-02-09 2013-02-05 Astellas Pharma Inc. Aza-bridged-ring compound
WO2008106694A2 (en) * 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US20100144538A1 (en) * 2007-03-08 2010-06-10 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
ES2363998T3 (es) 2007-03-23 2011-08-22 Abbott Laboratories Derivados ester y carbamato de azaadamantano y métodos de uso de los mismos.
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009058120A1 (en) 2007-11-02 2009-05-07 Sri International Nicotinic acetylcholine receptor modulators
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
EP2221306B1 (en) 2007-11-20 2016-04-13 Nissan Chemical Industries, Ltd. Method for producing 2-azaadamantane
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
EP2633868A1 (en) 2008-02-13 2013-09-04 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US20090239901A1 (en) * 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
CA2727141A1 (en) 2008-06-13 2009-12-17 Centre For Addiction And Mental Health Compositions and methods for modulating nicotinic/nmda receptor function
US8841329B2 (en) 2008-09-11 2014-09-23 Dignity Health Nicotinic attenuation of CNS inflammation and autoimmunity
US8435762B2 (en) * 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
EP2459562A1 (en) 2009-07-31 2012-06-06 Biocryst Pharmaceuticals, Inc. Pyrrolo [1, 2-b]pyridazine derivatives as janus kinase inhibitors
WO2011022467A2 (en) 2009-08-21 2011-02-24 University Of Florida Research Foundation, Inc. Controlled-release formulations of anabaseine compounds and uses thereof
WO2011044537A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
CN103554107B (zh) 2016-08-17
ECSP099388A (es) 2009-07-31
AU2007316480B2 (en) 2012-08-16
BRPI0718028A2 (pt) 2013-11-12
JP2010509239A (ja) 2010-03-25
EP2099795B1 (en) 2015-08-19
ZA200903944B (en) 2016-08-31
DOP2015000014A (es) 2015-04-15
IL198587A (en) 2013-10-31
US20080167336A1 (en) 2008-07-10
PL2099795T3 (pl) 2016-01-29
US8987453B2 (en) 2015-03-24
CO6210720A2 (es) 2010-10-20
JP5727651B2 (ja) 2015-06-03
JP5275246B2 (ja) 2013-08-28
HK1133645A1 (en) 2010-04-01
DOP2011000301A (es) 2011-10-31
WO2008058096A2 (en) 2008-05-15
MY148253A (en) 2013-03-29
RU2012102908A (ru) 2013-08-10
KR20150038647A (ko) 2015-04-08
TWI511729B (zh) 2015-12-11
NZ618134A (en) 2015-05-29
MX2009004813A (es) 2009-07-31
NZ577474A (en) 2012-03-30
NO20092181L (no) 2009-07-21
ZA201303483B (en) 2016-07-27
NZ589813A (en) 2012-11-30
SG176473A1 (en) 2011-12-29
CA2668962A1 (en) 2008-05-15
UA96961C2 (uk) 2011-12-26
KR20140116558A (ko) 2014-10-02
RU2009121564A (ru) 2010-12-20
IL198587A0 (en) 2010-02-17
PH12013500745A1 (en) 2016-06-27
CR20140277A (es) 2014-09-23
DK2099795T3 (en) 2015-12-07
PT2099795E (pt) 2015-11-24
DOP2015000264A (es) 2015-11-30
JP2013121969A (ja) 2013-06-20
JP2014193917A (ja) 2014-10-09
IL227668A0 (en) 2013-09-30
JP5562449B2 (ja) 2014-07-30
MX340064B (es) 2016-06-23
IL227668A (en) 2014-05-28
ES2551117T3 (es) 2015-11-16
WO2008058096A3 (en) 2008-08-07
NZ600178A (en) 2014-04-30
US20150158867A1 (en) 2015-06-11
JP2015143260A (ja) 2015-08-06
KR101636439B1 (ko) 2016-07-05
KR20140054300A (ko) 2014-05-08
WO2008058096A9 (en) 2008-06-26
RU2450002C2 (ru) 2012-05-10
CA2668962C (en) 2016-05-03
US20130096132A1 (en) 2013-04-18
EP2099795A2 (en) 2009-09-16
CN103554107A (zh) 2014-02-05
TW200829243A (en) 2008-07-16
US8314119B2 (en) 2012-11-20
ZA201008549B (en) 2014-07-30
KR20090111804A (ko) 2009-10-27
AU2007316480A1 (en) 2008-05-15
KR101654073B1 (ko) 2016-09-05

Similar Documents

Publication Publication Date Title
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0810522A2 (pt) Mimétricos diazo bicíclicos de smac e uso dos mesmos.
BRPI0810524A2 (pt) Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0720625A2 (pt) Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
ES2458216T8 (es) Nuevos ARNip y métodos de uso de los mismos
CR10709A (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CR10847A (es) Compuesto heteromonociclico y uso del mismo
BRPI0909954A2 (pt) &#34;diazacarbazóis e métodos de uso&#34;
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
ES2402220T8 (es) Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
CR10583A (es) Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
BRPI0821668A2 (pt) Uso
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0717411A2 (pt) Uso de inibidores de iap
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
CR10815A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas